The Italian Competition Authority launches an investigation against a cartel allegedly carried out by two pharmaceutical companies (Roche, Novartis)

The Italian Competition Authority launches an investigation against a cartel allegedly carried out by Roche and Novartis in the pharmaceutical market (Roche Novartis) The facts of the case The Italian Competition Authority (ICA) has opened an Article 101 TFEU proceedings against Roche and Novartis [1], upon receipt of two complaints lodged by an association of private health care providers and by the Italian Ophthalmological Society, respectively. The complainants alleged that Roche and Novartis had concluded an agreement to prevent the off-label commercial use of Avastin to the benefit to the approved but more expensive Lucentis. Avastin is a drug patented by the US Roche subsidiary, Genentech, for the treatment of

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteur

  • Desogus Law Office (Cagliari)

Citation

Michele Giannino, The Italian Competition Authority launches an investigation against a cartel allegedly carried out by two pharmaceutical companies (Roche, Novartis), 6 février 2013, e-Competitions February 2013, Art. N° 50997

Visites 441

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues